Floatz logo

Famotidine

Breast Carcinoma

Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB
Tamoxifen
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB

View all 50 →

Same molecule, other indications

Famotidine is also rated in:

sickle cell diseaseActive
BB
Indicative · Phase 2/3
65 / 100
View asset →
ulcer diseaseDormant
BB
Indicative · Phase 3
64 / 100
View asset →
schizophreniaDormant
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →